Thomas Malley Biography and Net Worth

Director of Kiniksa Pharmaceuticals International

Mr. Malley is the President of Mossrock Capital, LLC, a private investment firm in Denver, Colorado, since May 2007. Mr. Malley worked for Janus Mutual Funds in positions of increasing responsibility from April 1991 to May 2007. From January 1999 to May 2007, Mr. Malley served as the portfolio manager of the Janus Global Life Sciences Fund, and also led the Janus Healthcare team of analysts. From 1991 to 1998 Mr. Malley served as an equity analyst for Janus covering, among others, healthcare and biotechnology stocks. Mr. Malley serves on the board of directors of BeiGene, Ltd. and Kura Oncology, Inc. both which are publicly-traded biotechnology companies. In the past, he served on the boards of OvaScience, Inc., Cougar Biotechnology, Puma Biotechnology and Synageva BioPharma Corp., all publicly-traded biotechnology companies. Mr. Malley holds a B.S. degree in Biology from Stanford University.

What is Thomas Malley's net worth?: The estimated net worth of Thomas Malley is at least $514.26 thousand as of August 14th, 2025. Mr. Malley owns 12,546 shares of Kiniksa Pharmaceuticals International stock worth more than $514,261 as of December 4th. This net worth evaluation does not reflect any other investments that Mr. Malley may own. Learn More about Thomas Malley's net worth.
How do I contact Thomas Malley?: The corporate mailing address for Mr. Malley and other Kiniksa Pharmaceuticals International executives is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. Kiniksa Pharmaceuticals International can also be reached via phone at (781) 431-9100 and via email at [email protected]. Learn More on Thomas Malley's contact information.
Has Thomas Malley been buying or selling shares of Kiniksa Pharmaceuticals International?: Thomas Malley has not been actively trading shares of Kiniksa Pharmaceuticals International within the last three months. Most recently, Thomas Malley sold 78,233 shares of the business's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $33.09, for a transaction totalling $2,588,729.97. Following the completion of the sale, the director now directly owns 12,546 shares of the company's stock, valued at $415,147.14. Learn More on Thomas Malley's trading history.
Who are Kiniksa Pharmaceuticals International's active insiders?: Kiniksa Pharmaceuticals International's insider roster includes Thomas Malley (Director), Michael Megna (Group Vice President of Finance and Chief Accounting Officer), Ross Moat (Executive Vice President, Chief Commercial Officer), John Paolini (Executive Vice President, Chief Medical Officer), Sanj Patel (CEO and Chairman of the Board), Barry Quart (Director), Mark Ragosa (CFO), and Eben Tessari (https://monarchcasino.com/corporategovernance_boardofdirectors.asp). Learn More on Kiniksa Pharmaceuticals International's active insiders.
Are insiders buying or selling shares of Kiniksa Pharmaceuticals International?: In the last year, insiders at the sold shares 57 times. They sold a total of 1,575,162 shares worth more than $51,430,265.98. The most recent insider tranaction occured on November, 26th when COO Eben Tessari sold 200 shares worth more than $8,578.00. Insiders at Kiniksa Pharmaceuticals International own 53.5% of the company. Learn More about insider trades at Kiniksa Pharmaceuticals International.
Information on this page was last updated on 11/26/2025.

Thomas Malley Insider Trading History at Kiniksa Pharmaceuticals International

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/14/2025	Sell	78,233	$33.09	$2,588,729.97	12,546
8/13/2025	Sell	50,129	$33.32	$1,670,298.28	12,546
8/12/2025	Sell	49,407	$32.40	$1,600,786.80	12,546

Thomas Malley Buying and Selling Activity at Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International Company Overview

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Today's Range

Now: $40.99

$39.79

$41.48

50 Day Range

MA: $39.46

$36.49

$42.71

2 Week Range

Now: $40.99

$17.82

$42.98

Volume

331,068 shs

Average Volume

299,683 shs

Market Capitalization

$3.11 billion

P/E Ratio

91.09

Dividend Yield

N/A

Beta

0.02